Skip to content
HowShorted

RIGEL PHARMACEUTICALS INC short interest in 2019

In 2019, RIGEL PHARMACEUTICALS INC's disclosed short interest ran from 9.11% of shares outstanding on 15 Jan 2019 to 6.61% on 31 Dec 2019, a change of -2.50 percentage points. The year's high was 12.18% on 31 May 2019 and its low 5.88% on 31 Oct 2019, averaging 8.16% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.82 days on 15 Jul 2019. Full history: RIGEL PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for RIGEL PHARMACEUTICALS INC in 2019

2019 in figures

Start of year
9.11% (15 Jan 2019)
End of year
6.61% (31 Dec 2019)
Change
-2.50 pp
High
12.18% (31 May 2019)
Low
5.88% (31 Oct 2019)
Average
8.16%
Highest days to cover
13.82 (15 Jul 2019)
SEC filings marked
10

Every report in 2019

RIGEL PHARMACEUTICALS INC short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 20199.11%6.03results (8-K)
31 Jan 20198.51%4.75
15 Feb 20198.79%8.46
28 Feb 20198.82%9.5310-K filed, results (8-K)
15 Mar 20199.33%8.07
29 Mar 20199.13%9.61
15 Apr 20199.05%12.14
30 Apr 20198.92%9.21
15 May 201911.28%11.1510-Q filed, results (8-K)
31 May 201912.18%11.80
14 Jun 20198.83%13.36
28 Jun 20198.01%8.44
15 Jul 20197.78%13.82
31 Jul 20197.14%13.15
15 Aug 20197.53%10.8310-Q filed, results (8-K)
30 Aug 20197.66%12.86
13 Sep 20197.64%7.29
30 Sep 20196.94%6.27
15 Oct 20196.57%10.00
31 Oct 20195.88%4.91results (8-K)
15 Nov 20196.25%9.1710-Q filed, results (8-K)
29 Nov 20196.71%8.54
13 Dec 20197.07%11.32
31 Dec 20196.61%7.84

See also: RIGEL PHARMACEUTICALS INC's full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.